AstraZeneca India is set to establish an Integrated Genomic Solutions Centre in Amaravati, marking a new step in the use of genomic medicine for cancer care. The project is aimed at strengthening precision oncology in India by linking advanced genetic research with clinical decision-making.
According to the announcement, the initiative is designed to introduce the country’s first Integrated Precision Oncology programme. The focus is on enabling more personalised cancer diagnosis and treatment, using genomic insights to help identify disease patterns and support more tailored care.
The Andhra Pradesh government has signed an agreement as part of the effort to bring the centre to Amaravati. The move highlights the state’s push to support healthcare innovation while creating a base for advanced cancer-focused research and diagnostic capabilities.
The planned centre reflects growing interest in precision medicine, where treatment strategies are informed by a patient’s genetic profile. If implemented as outlined, the Amaravati facility could become an important platform for expanding genomic approaches in cancer care across India.
